NANJING, China, June 1, 2025 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of...
Hence then, the article about inxmed announces promising phase ib ii clinical data for ifebemtinib kras g12c inhibitor in kras g12c mutant solid tumors at asco 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib + KRAS G12C inhibitor in KRAS G12C-Mutant Solid Tumors at ASCO 2025 )
Also on site :
- Figma announces new features to define how agents work on its platform
- Container ship sinks in Hormuz mine strike amid US-Iran naval clashes (VIDEOS)
- Alan Mandell, Esteemed Actor and Interpreter of Samuel Beckett Plays, Dies at 98